Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Pharmaceutical Firms Rally

Wed, 04th Nov 2020 10:38

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - WINNERS

----------

AstraZeneca, up 4.3%, Hikma, up 4.0% and GlaxoSmithKline, 2.6% higher. Pharmaceutical firms, often touted as defensive stocks, were on the up early on Wednesday following a volatile start for the FTSE 100 amid a tight and hard-to-call US election result. A "blue wave" sweep by Democrats might have brought more regulation for the pharmaceutical industry.

----------

FTSE 100 - LOSERS

----------

HSBC and Standard Chartered, down 3.4% and 5.2%. The two banking stocks were at the FTSE 100 on Wednesday morning, amid the political tensions in the US, giving back gains from Tuesday when they closed 4.3% higher and 3.9% higher, respectively.

----------

FTSE 250 - WINNERS

----------

Royal Mail, up 8.0%. The postal service provider surged after JPMorgan raised the stock to Overweight from Neutral.

----------

Marks & Spencer, up 4.8%. The retailer's interim performance was better than expected, despite swinging to a pretax loss of GBP87.6 million from a GBP158.8 million profit. Revenue for the six months to September declined 16% to GBP4.09 billion from GBP4.86 billion a year before.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Stobart Group, up 9.4%. The logistics, energy and aviation firm was hit by a reduction in passenger travel at Southend Airport. Revenue in the six months ended August dropped 29% to GBP53.2 million from GBP74.8 million, and Stobart's pretax loss ballooned to GBP77.4 million from GBP15.5 million. The company however, affirmed that it "remains focused on exiting Stobart Air" and is in talks with parties to dispose of its stake.

----------

Wishbone Gold, up 70%. The exploration firm said that geological consultants Terra Search spotted four magnetic targets, covering a total of 2.4 kilometres by 400 metres, at the Patersons Range gold project in Australia. Wishbone added that it has completed due diligence to acquire the project and will now move towards closing the acquisition.

----------

Gattaca, up 37%. The engineering and technology recruitment services firm said revenue slipped 15% in the year ended July 31 to GBP538.7 million from GBP634.3 million. Pretax profit fell 57% to GBP1.4 million from GBP3.4 million. But notes it will carry out an improvement plan which will see its Technology unit restructured. Adds that it will deliver GBP4 million in annual savings from costs during the year to November.

----------

CPL Resources, up 34% to 951.50 pence. The Dublin-based human resources firm has accepted a EUR317.8 million takeover from Outsourcing, a Tokyo-listed HR services provider. The EUR11.25 per share offer is a 36% premium to CPL closing price on Tuesday.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Tern, down 10%. The internet of things-focused investor announced a GBP860,000 investment to take a 23% stake in Talking Medicines, a provider of AI and machine learning services to the pharmaceutical industry.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.